Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL2319232

N.Nc1cc(Cl)ccc1C(=O)O

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.61
TSHR P16473 3/20 0.61
CASP1 P29466 1/20 0.61
ABL1 P00519 1/20 0.59
CYP3A4 P08684 3/20 0.57
ALDH1A1 P00352 6/20 0.55
TP53 P04637 2/20 0.55
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
HPGD P15428 3/20 0.53
POLB P06746 1/20 0.53
GAA P10253 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
HSD17B10 Q99714 2/20 0.52
KDM4E B2RXH2 2/20 0.52
ALOX15 P16050 3/20 0.50
TDP1 Q9NUW8 2/20 0.50
FLT1 P17948 1/20 0.50
FLT4 P35916 1/20 0.50
KDR P35968 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL128885 0.98 SMN1; SMN2 (0.63) SMN1; SMN2TSHRCASP1ABL1CYP3A4
SCHEMBL28303002 0.96 SMN1; SMN2 (0.61) SMN1; SMN2TSHRCASP1ABL1CYP3A4
Hydrochloric Acid SCHEMBL6750016 0.96 SMN1; SMN2 (0.61) SMN1; SMN2TSHRCASP1ABL1CYP3A4
Ethane SCHEMBL11678007 0.94 ABL1 (0.62) SMN1; SMN2TSHRCASP1ABL1CYP3A4
Nitrogen SCHEMBL28649098 0.94 SMN1; SMN2 (0.59) SMN1; SMN2TSHRCASP1ABL1CYP3A4
3,5-Dichloroanthranilic Acid SCHEMBL10496322 0.84 TSHR (0.58) SMN1; SMN2TSHRCASP1ABL1CYP3A4
Ammonia Solution, Strong SCHEMBL2320305 0.83 ALDH1A1 (0.61) SMN1; SMN2TSHRCASP1CYP3A4ALDH1A1
SCHEMBL2722648 0.82 PPM1B (0.67) SMN1; SMN2TSHRCASP1ABL1CYP3A4
3-Aminobenzoic Acid SCHEMBL10434170 0.82 PBRM1 (0.47) SMN1; SMN2TSHRCASP1ABL1CYP3A4
SCHEMBL31542015 0.81 ALDH1A1 (0.63) SMN1; SMN2TSHRCASP1CYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1466907-B1 PROCESS FOR PRODUCING QUINAZOLIN-4-ONE AND DERIVATIVE THEREOF UBE INDUSTRIES (JP) 2011-08-10 EP disclosed
US-7232903-B2 Process for producing quinazolin-4-one and derivatives thereof UBE INDUSTRIES, LTD. (JP) 2007-06-19 US disclosed
US-20050124809-A1 Process for producing quinazolin-4-one and derivatives thereof UBE INDUSTRIES, LTD. (JP) 2005-06-09 US disclosed
EP-1466907-A1 PROCESS FOR PRODUCING QUINAZOLIN-4-ONE AND DERIVATIVE THEREOF Ube Industries, Ltd. (JP) 2004-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124809-A1 Process for producing quinazolin-4-one and derivatives thereof ASNS, NQO2, KYNU SMN1; SMN2 4739/4885TSHR 4406/4885CASP1 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.